Skip to main content

Advertisement

Log in

Endocrine Therapy for Growth Retardation in Paediatric Inflammatory Bowel Disease

  • Review Article
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Inflammatory bowel disease, particularly Crohn’s disease (CD), can potentially cause growth failure during childhood as well as a reduction in final adult height. The underlying mechanism is multifactorial and includes poor nutrition, chronic inflammation, and the prolonged use of steroids. Despite major advances in the treatment of CD, current cohorts of children continue to display a deficit in linear growth and may qualify for growth-promoting hormonal therapy. However, currently there is limited evidence to support the use of endocrine therapy directed primarily at improving growth. This review is aimed at summarising the current evidence for growth impairment in inflammatory bowel disease and discusses the rationale for using growth promoting therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

References

  1. Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504–17.

    Article  PubMed  Google Scholar 

  2. Walters TD, Griffiths AM. Mechanisms of growth impairment in pediatric Crohn’s disease. Nat Rev Gastroenterol Hepatol. 2009;6(9):513–23.

    Article  CAS  PubMed  Google Scholar 

  3. Ahmed SF, Farquharson C, McGrogan P, Russell RK. Pathophysiology and management of abnormal growth in children with chronic inflammatory bowel disease. World Rev Nutr Diet 2013;106:142-8. doi:10.1159/000342529. Epub 2013 Feb 11

  4. Malik S, Mason A, Bakhshi A, Young D, Bishop J, Garrick V, et al. Growth in children receiving contemporary disease specific therapy for Crohn’s disease. Arch Dis Child. 2012;97(8):698–703.

    Article  PubMed  Google Scholar 

  5. Pfefferkorn M, Burke G, Griffiths A, Markowitz J, Rosh J, Mack D, et al. Growth abnormalities persist in newly diagnosed children with Crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr. 2009;48(2):168–74.

    Article  CAS  PubMed  Google Scholar 

  6. Mason A, Wong SC, McGrogan P, Ahmed SF. Effect of testosterone therapy for delayed growth and puberty in boys with inflammatory bowel disease. Horm Res Paediatr. 2011;75(1):8–13.

    Article  CAS  PubMed  Google Scholar 

  7. Belli DC, Seidman E, Bouthillier L, Weber AM, Roy CC, Pletincx M, et al. Chronic intermittent elemental diet improves growth failure in children with Crohn’s-disease. Gastroenterology. 1988;94(3):603–10.

    CAS  PubMed  Google Scholar 

  8. Polk DB, Hattner JAT, Kerner JA. Improved growth and disease-activity after intermittent administration of a defined formula diet in children with Crohn’s-disease. J Parenter Enter Nutr. 1992;16(6):499–504.

    Article  CAS  Google Scholar 

  9. Morris NM, Udry JR. Validation of a self-administered instrument to assess stage of adolescent development. J Youth Adolesc. 1980;9(3):271–80.

    Article  CAS  PubMed  Google Scholar 

  10. Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17(6):1314–21.

    Article  PubMed  Google Scholar 

  11. Wong SC, Macrae VE, McGrogan P, Ahmed SF. The role of pro-inflammatory cytokines in inflammatory bowel disease growth retardation. J Pediatr Gastroenterol Nutr. 2006;43(2):144–55.

    Article  CAS  PubMed  Google Scholar 

  12. Heuschkel R, Salvestrini C, Beattie RM, Hildebrand H, Walters T, Griffiths A. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(6):839–49.

    Article  PubMed  Google Scholar 

  13. Gupta N, Lustig RH, Kohn M, Vittinghoff E. Determination of bone age in pediatric patients with Crohn’s disease should be a part of routine care. Gastroenterology. 2012;142(5):S372.

    Google Scholar 

  14. Ezri J, Marques-Vidal P, Nydegger A. Impact of disease and treatments on growth and puberty of pediatric patients with inflammatory bowel disease. Digestion. 2012;85(4):308–19.

    Article  CAS  PubMed  Google Scholar 

  15. Abraham BP, Mehta S, El-Serag HB. Natural history of pediatric-onset inflammatory bowel disease a systematic review. J Clin Gastroenterol. 2012;46(7):581–9.

    Article  PubMed  Google Scholar 

  16. Lee JJ, Escher JC, Shuman MJ, Forbes PW, Delemarre LC, Harr BW, et al. Final adult height of children with inflammatory bowel disease is predicted by parental height and patient minimum height Z-score. Inflamm Bowel Dis. 2010;16(10):1669–77.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Sawczenko A, Ballinger AB, Savage MO, Sanderson IR. Clinical features affecting final adult height in patients with pediatric-onset Crohn’s disease. Pediatrics. 2006;118(1):124–9.

    Article  PubMed  Google Scholar 

  18. D’Mello S, Trauernicht A, Ryan A, Bonkowski E, Willson T, Trapnell BC, et al. Innate dysfunction promotes linear growth failure in pediatric Crohn’s disease and growth hormone resistance in murine ileitis. Inflamm Bowel Dis. 2012;18(2):236–45.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Bousvaros A, Sylvester F, Kugathasan S, Szigethy E, Fiocchi C, Colletti R, et al. Challenges in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2006;12(9):885–913.

    Article  PubMed  Google Scholar 

  20. Farquharson C, Ahmed SF. Inflammation and linear bone growth: the inhibitory role of SOCS2 on GH/IGF-1 signaling. Pediatr Nephrol. 2013;28(4):547–56.

    Article  PubMed  Google Scholar 

  21. Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol. 2001;229(1):141–62.

    Article  CAS  PubMed  Google Scholar 

  22. Liu JL, Yakar S, LeRoith D. Conditional knockout of mouse insulin-like growth factor-1 gene using the Cre/loxP system. Proc Soc Exp Biol Med. 2000;223(4):344.

    Article  CAS  PubMed  Google Scholar 

  23. Marcovecchio ML, Mohn A, Chiarelli F. Inflammatory cytokines and growth in childhood. Curr Opin Endocrinol Diabetes Obes. 2012;19(1):57–62.

    Article  CAS  PubMed  Google Scholar 

  24. Wong SC, Smyth A, McNeill E, Galloway PJ, Hassan K, McGrogan P, et al. The growth hormone insulin-like growth factor 1 axis in children and adolescents with inflammatory bowel disease and growth retardation. Clin Endocrinol. 2010;73(2):220–8.

    CAS  Google Scholar 

  25. Chong SKF, Grossman A, Walkersmith JA, Rees LH. Endocrine dysfunction in children with Crohn’s-disease. J Pediatr Gastroenterol Nutr. 1984;3(4):529–34.

    Article  CAS  PubMed  Google Scholar 

  26. Thomas AG, Holly JM, Taylor FF, Miller V. Insulin like growth factor-I, insulin like growth factor binding protein-1, and insulin in childhood Crohn’s disease. Gut 1993 Jul;34(7):944-7

  27. Russell RK, Drummond HE, Nimmo ER, Anderson NH, Noble CL, Wilson DC, et al. Analysis of the influence of OCTN1/2 variants within the IBD5 locus on disease susceptibility and growth indices in early onset inflammatory bowel disease. Gut. 2006;55(8):1114–23.

    Article  CAS  PubMed  Google Scholar 

  28. Sawczenko A, Azooz O, Paraszczuk J, Idestrom M, Croft NM, Savage MO, et al. Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the-174 IL-6 G/C polymorphism in children. Proc Natl Acad Sci USA. 2005;102(37):13260–5.

    Article  CAS  PubMed  Google Scholar 

  29. Levine A, Shamir R, Wine E, Weiss B, Karban A, Shaoul RR, et al. TNF promoter polymorphisms and modulation of growth retardation and disease severity in pediatric Crohn’s disease. Am J Gastroenterol. 2005;100(7):1598–604.

    Article  CAS  PubMed  Google Scholar 

  30. Shamir R. Nutrition and growth in inflammatory bowel disease. World Rev Nutr Diet. 2013;106:156–61.

    PubMed  Google Scholar 

  31. Shamir R. Nutrition and growth in inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2010;51:S131–2.

    Article  PubMed  Google Scholar 

  32. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth-factors. Endocr Rev. 1994;15(1):80–101.

    CAS  PubMed  Google Scholar 

  33. Sermet-Gaudelus I, Souberbielle JC, Azhar I, Ruiz JC, Magnine P, Colomb V, et al. Insulin-like growth factor I correlates with lean body mass in cystic fibrosis patients. Arch Dis Child. 2003;88(11):956–61.

    Article  CAS  PubMed  Google Scholar 

  34. Smith WJ, Underwood LE, Clemmons DR. Effects of caloric or protein restriction on insulin-like growth-factor-I (IGF-I) and IGF-binding proteins in children and adults. J Clin Endocrinol Metab. 1995;80(2):443–9.

    CAS  PubMed  Google Scholar 

  35. Ballinger AB, Azooz O, El-Hajh T, Poole S, Farthing MJG. Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut. 2000;46(5):694–700.

    Article  CAS  PubMed  Google Scholar 

  36. Ahmed SF, Savendahl L. Promoting growth in chronic inflammatory disease: lessons from studies of the growth plate. Horm Res. 2009;72:42–7.

    Article  CAS  PubMed  Google Scholar 

  37. DeBenedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I—a model for stunted growth in children with chronic inflammation. J Clin Investig. 1997;99(4):643–50.

    Article  CAS  Google Scholar 

  38. Thayu M, Denson LA, Shults J, Zemel BS, Burnham JM, Baldassano RN, et al. Determinants of changes in linear growth and body composition in incident pediatric Crohn’s disease. Gastroenterology. 2010;139(2):430–8.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Ahmed SF, Farquharson C. The effect of GH and IGF1 on linear growth and skeletal development and their modulation by SOCS proteins. J Endocrinol. 2010;206(3):249–59.

    Article  CAS  PubMed  Google Scholar 

  40. Pass C, Macrae VE, Huesa C, Ahmed SF, Farquharson C. SOCS2 is the critical regulator of GH action in murine growth plate chondrogenesis. J Bone Miner Res. 2012;27(5):1055–66.

    Article  CAS  PubMed  Google Scholar 

  41. Martensson K, Chrysis D, Savendahl L. Interleukin-1 beta and TNF-alpha act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones. J Bone Miner Res. 2004;19(11):1805–12.

    Article  CAS  PubMed  Google Scholar 

  42. Macrae VE, Farquharson C, Ahmed SF. The restricted potential for recovery of growth plate chondrogenesis and longitudinal bone growth following exposure to pro-inflammatory cytokines. J Endocrinol. 2006;189(2):319–28.

    Article  CAS  PubMed  Google Scholar 

  43. Macrae VE, Ahmed SF, Mushtaq T, Farquharson C. IGF-I signalling in bone growth: inhibitory actions of dexamethasone and IL-1 beta. Growth Horm Igf Res. 2007;17(5):435–9.

    Article  CAS  PubMed  Google Scholar 

  44. Shamir R, Phillip M, Levine A. Growth retardation in pediatric Crohn’s disease: pathogenesis and interventions. Inflamm Bowel Dis. 2007;13(5):620–8.

    Article  PubMed  Google Scholar 

  45. Homer DR, Grand RJ, Colodny AH. Growth, course, and prognosis after surgery for Crohn’s-disease in children and adolescents. Pediatrics. 1977;59(5):717–25.

    CAS  PubMed  Google Scholar 

  46. Sentongo TA, Stettler N, Christian A, Han PD, Stallings VA, Baldassano RN. Growth after intestinal resection for Crohn’s disease in children, adolescents, and young adults. Inflamm Bowel Dis. 2000;6(4):265–9.

    CAS  PubMed  Google Scholar 

  47. Canani RB, Terrin G, Borrelli O, Romano MT, Manguso F, Coruzzo A, et al. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn’s disease. Dig Liver Dis. 2006;38(6):381–7.

    Article  CAS  Google Scholar 

  48. Lambert B, Lemberg DA, Leach ST, Day AS. Longer-term outcomes of nutritional management of Crohn’s disease in children. Dig Dis Sci. 2012;57(8):2171–7.

    Article  CAS  PubMed  Google Scholar 

  49. Mushtaq T, Ahmed SF. The impact of corticosteroids on growth and bone health. Arch Dis Child. 2002;87(2):93–6.

    Article  CAS  PubMed  Google Scholar 

  50. Kritsch KR, Murali S, Adamo ML, Ney DM. Dexamethasone decreases serum and liver IGF-I and maintains liver IGF-I mRNA in parenterally fed rats. Am J Physiol Regul Integr Comp Physiol. 2002;282(2):R528–36.

    CAS  PubMed  Google Scholar 

  51. Jux C, Leiber K, Hugel U, Blum W, Ohlsson C, Klaus G, et al. Dexamethasone impairs growth hormone (GH)-stimulated growth by suppression of local insulin-like growth factor (IGF)-I production and expression of GH- and IGF-I-receptor in cultured rat chondrocytes. Endocrinology. 1998;139(7):3296–305.

    CAS  PubMed  Google Scholar 

  52. Chrysis D, Zaman F, Chagin AS, Takigawa M, Savendahl L. Dexamethasone induces apoptosis in proliferative chondrocytes through activation of caspases and suppression of the Akt-phosphatidylinositol 3 ‘-kinase signaling pathway. Endocrinology. 2005;146(3):1391–7.

    Article  CAS  PubMed  Google Scholar 

  53. Mushtaq T, Farquharson C, Seawright E, Ahmed SF. Glucocorticoid effects on chondrogenesis, differentiation and apoptosis in the murine ATDC5 chondrocyte cell line. J Endocrinol. 2002;175(3):705–13.

    Article  CAS  PubMed  Google Scholar 

  54. Mushtaq T, Bijman P, Ahmed SF, Farquharson C. Insulin-like growth factor-I augments chondrocyte hypertrophy and reverses glucocorticoid-mediated growth retardation in fetal mice metatarsal cultures. Endocrinology. 2004;145(5):2478–86.

    Article  CAS  PubMed  Google Scholar 

  55. Kamischke A, Kemper DE, Castel MA, Luthke M, Rolf C, Behre HM, et al. Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur Respir J. 1998;11(1):41–5.

    Article  CAS  PubMed  Google Scholar 

  56. Perry RJ, Farquharson C, Ahmed SF. The role of sex steroids in controlling pubertal growth. Clin Endocrinol. 2008;68(1):4–15.

    Article  CAS  Google Scholar 

  57. Brain CE, Savage MO. Growth and puberty in chronic inflammatory bowel-disease. Baillieres Clin Gastroenterol. 1994;8(1):83–100.

    Article  CAS  PubMed  Google Scholar 

  58. Mason A, Malik S, Russell RK, Bishop J, McGrogan P, Ahmed SF. Impact of inflammatory bowel disease on pubertal growth. Horm Res Paediatr. 2011;76(5):293–9.

    Article  CAS  PubMed  Google Scholar 

  59. Azooz OG, Farthing MJG, Savage MO, Ballinger AB. Delayed puberty and response to testosterone in a rat model of colitis. Am J Physiol Regul Integr Comp Physiol. 2001;281(5):R1483–91.

    CAS  PubMed  Google Scholar 

  60. Deboer MD, Li YL. Puberty is delayed in male mice with dextran sodium sulfate colitis out of proportion to changes in food intake, body weight, and serum levels of leptin. Pediatr Res. 2011;69(1):34–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  61. Morales V, Santana P, Diaz R, Tabraue C, Gallardo G, Blanco FL, et al. Intratesticular delivery of tumor necrosis factor-alpha and ceramide directly abrogates steroidogenic acute regulatory protein expression and Leydig cell steroidogenesis in adult rats. Endocrinology. 2003;144(11):4763–72.

    Article  CAS  PubMed  Google Scholar 

  62. Day AS, Whitten KE, Sidler M, Lemberg DA. Systematic review: nutritional therapy in paediatric Crohn’s disease. Aliment Pharmacol Ther. 2008;27(4):293–307.

    Article  CAS  PubMed  Google Scholar 

  63. Papadopoulou A, Rawashdeh MO, Brown GA, Mcneish AS, Booth IW. Remission following an elemental diet or prednisolone in Crohn’s-disease. Acta Paediatrica. 1995;84(1):79–83.

    Article  CAS  PubMed  Google Scholar 

  64. Bannerjee T, Camacho-Hubner C, Babinska K, Dryhurst KM, Edwards R, Savage MO, et al. Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J Pediatr Gastroenterol Nutr. 2004;38(3):270–5.

    Article  CAS  PubMed  Google Scholar 

  65. Fell JME, Paintin M, Arnaud-Battandier F, Beattie RM, Hollis A, Kitching P, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn’s disease. Aliment Pharmacol Ther. 2000;14(3):281–9.

    Article  CAS  PubMed  Google Scholar 

  66. Meister D, Bode J, Shand A, Ghosh S. Anti-inflammatory effects of enteral diet components on Crohn’s disease-affected tissues in vitro. Dig Liver Dis. 2002;34(6):430–8.

    Article  CAS  PubMed  Google Scholar 

  67. Cameron FL, Gerasimidis K, Papangelou A, Missiou D, Garrick V, Cardigan T, et al. Clinical progress in the two years following a course of exclusive enteral nutrition in 109 paediatric patients with Crohn’s disease. Aliment Pharmacol Ther. 2013;37(6):622–9.

    Article  CAS  PubMed  Google Scholar 

  68. de Bie CI, Escher JC, de Ridder L. Antitumor necrosis factor treatment for pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(5):985–1002.

    Article  PubMed  Google Scholar 

  69. Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology. 2007;132(3):863–73.

    Article  CAS  PubMed  Google Scholar 

  70. Borrelli O, Bascietto C, Viola F, de Mesquita MB, Barbato M, Mancini V, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn’s disease. Dig Liver Dis. 2004;36(5):342–7.

    Article  CAS  PubMed  Google Scholar 

  71. Assa A, Hartman C, Weiss B, Broide E, Rosenbach Y, Rosenbach Y, Zevit N, et al. Long-term outcome of tumor necrosis factor alpha antagonist’s treatment in pediatric Crohn’s disease. J Crohns Colitis 2013 Jun;7(5):369-76

  72. Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn’s disease. Inflamm Bowel Dis. 2007;13(4):424–30.

    Article  PubMed  Google Scholar 

  73. Cezard JP, Nouaili N, Talbotec C, Hugot JP, Gobert JG, Schmitz J, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2003;36(5):632–6.

    Article  CAS  PubMed  Google Scholar 

  74. Malik S, Wong SC, Bishop J, Hassan K, McGrogan P, Ahmed SF, et al. Improvement in growth of children with Crohn disease following anti-TNF-alpha therapy can be independent of pubertal progress and glucocorticoid reduction. J Pediatr Gastroenterol Nutr. 2011;52(1):31–7.

    Article  CAS  PubMed  Google Scholar 

  75. Crombe V, Salleron J, Savoye G, Dupas JL, Vernier-Massouille G, Lerebours E, et al. Long-term outcome of treatment with infliximab in pediatric-onset Crohn’s disease: a population-based study. Inflamm Bowel Dis. 2011;17(10):2144–52.

    Article  PubMed  Google Scholar 

  76. Gentilucci UV, Caviglia R, Picardi A, Carotti S, Ribolsi M, Galati G, et al. Infliximab reverses growth hormone resistance associated with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;21(9):1063–71.

    Article  CAS  Google Scholar 

  77. Malik S, Ahmed SF, Wilson ML, Shah N, Loganathan S, Naik S, et al. The effects of anti-TNF-alpha treatment with adalimumab on growth in children with Crohn’s disease (CD). J Crohns Colitis. 2012;6(3):337–44.

    Article  CAS  PubMed  Google Scholar 

  78. Diamanti A, Basso M, Gambarara M, Papadatou B, Bracci F, Noto C, et al. Positive impact of blocking tumor necrosis factor alpha on the nutritional status in pediatric Crohn’s disease patients. Int J Colorectal Dis. 2009;24(1):19–25.

    Article  CAS  PubMed  Google Scholar 

  79. Sinitsky DM, Lemberg DA, Leach ST, Bohane TD, Jackson R, Day AS. Infliximab improves inflammation and anthropometric measures in pediatric Crohn’s disease. J Gastroenterol Hepatol. 2010;25(4):810–6.

    Article  CAS  PubMed  Google Scholar 

  80. Wewer V, Riis T, Vind I, Husby T, Munkholm P, Paerregaard A. Infliximab dependency in a national cohort of children with Crohn’s disease. J Pediatric Gastroenterol Nutr. 2006;42(1):40–5.

    Article  CAS  Google Scholar 

  81. Landon C, Rosenfeld RG. Short stature and pubertal delay in male-adolescents with cystic-fibrosis—androgen treatment. Am J Dise Child. 1984;138(4):388–91.

    Article  CAS  Google Scholar 

  82. Hardin DS, Kemp SF, Allen DB. Twenty years of recombinant human growth hormone in children: Relevance to pediatric care providers. Clin Pediatr. 2007;46(4):279–86.

    Article  Google Scholar 

  83. Phung OJ, Coleman CI, Baker EL, Scholle JM, Girotto JE, Makanji SS, et al. Recombinant human growth hormone in the treatment of patients with cystic fibrosis. Pediatrics. 2010;126(5):E1211–26.

    Article  PubMed  Google Scholar 

  84. Simon D, Bechtold S. Effects of growth hormone treatment on growth in children with juvenile idiopathic arthritis. Horm Res. 2009;72:55–9.

    Article  CAS  PubMed  Google Scholar 

  85. Calenda KA, Schornagel IL, Sadeghi-Nejad A, Grand RJ. Effect of recombinant growth hormone treatment on children with Crohn’s disease and short stature: a pilot study. Inflamm Bowel Dis. 2005;11(5):435–41.

    Article  PubMed  Google Scholar 

  86. Denson LA, Kim MO, Bezold R, Carey R, Osuntokun B, Nylund C, et al. A randomized controlled trial of growth hormone in active pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2010;51(2):130–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  87. Heyman MB, Garnett EA, Wojcicki J, Gupta N, Davis C, Cohen SA, et al. Growth hormone treatment for growth failure in pediatric patients with Crohn’s disease. J Pediatr. 2008;153(5):651–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  88. Mauras N. Growth hormone therapy in the glucocorticosteroid-dependent child: metabolic and linear growth effects. Horm Res. 2001;56:13–8.

    Article  CAS  PubMed  Google Scholar 

  89. Wong SC, Kumar P, Galloway PJ, Blair JC, Didi M, Dalzell AM, et al. A preliminary trial of the effect of recombinant human growth hormone on short-term linear growth and glucose homeostasis in children with Crohn’s disease. Clin Endocrinol. 2011;74(5):599–607.

    Article  CAS  Google Scholar 

  90. McCaffer TD, Nasr K, Lawrence AM, Kirsner JB. Effect of administered human growth-hormone on growth retardation in inflammatory bowel-disease. Am J Dig Dis. 1974;19(5):411–6.

    Article  Google Scholar 

  91. Kara E, Sungurtekin H, Sungurtekin U, Alkanat M, Ilkgul O. The effect of recombinant human growth hormone (rhGH) on trinitrobenzene sulfonic acid-induced colitis in rats—an experimental study. Inflamm Bowel Dis. 2004;10(2):112–5.

    Article  PubMed  Google Scholar 

  92. Slonim AE, Bulone L, Damore MB, Goldberg T, Wingertzahn MA, McKinley MJ. A preliminary study of growth hormone therapy for Crohn’s disease. N Engl J Med. 2000;342(22):1633–7.

    Article  CAS  PubMed  Google Scholar 

  93. Bismuth E, Chevenne D, Czernichow P, Simon D. Moderate deterioration in glucose tolerance during high-dose growth hormone therapy in glucocorticoid-treated patients with juvenile idiopathic arthritis. Horm Res Paediatr. 2010;73(6):465–72.

    Article  CAS  PubMed  Google Scholar 

  94. Kupfer SR, Underwood LE, Baxter RC, Clemmons DR. Enhancement of the anabolic effects of growth-hormone and insulin-like growth factor-I by use of both agents simultaneously. J Clin Investig. 1993;91(2):391–6.

    Article  CAS  PubMed  Google Scholar 

  95. Grofte T, Wolthers T, Jensen SA, Moller N, Jorgensen JOL, Tygstrup N, et al. Effects of growth hormone and insulin-like growth factor-I singly and in combination on in vivo capacity of urea synthesis, gene expression of urea cycle enzymes, and organ nitrogen contents in rats. Hepatology. 1997;25(4):964–9.

    Article  CAS  PubMed  Google Scholar 

  96. Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. Brit J Pharmacol. 2008;154(3):557–68.

    Article  CAS  Google Scholar 

  97. Kovacs GT, Oh J, Kovacs J, Tonshoff B, Hunziker EB, Zapf J, et al. Growth promoting effects of growth hormone and IGF-I are additive in experimental uremia. Kidney Int. 1996;49(5):1413–21.

    Article  CAS  PubMed  Google Scholar 

  98. Wieser V, Moschen AR, Tilg H. Inflammation, cytokines and insulin resistance: a clinical perspective. Archivum Immunologiae et Therapiae Experimentalis. 2013;61(2):119–25.

    Article  CAS  PubMed  Google Scholar 

  99. Bucuvalas JC, Chernausek SD, Alfaro MP, Krug SK, Ritschel T, Wilmott RW. Effect of insulin like growth factor-1 treatment in children with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2001;33(5):576–81.

    Article  CAS  PubMed  Google Scholar 

  100. Rao AF, Standing JF, Naik S, Savage MO, Sanderson IR. Mathematical modelling to restore circulating IGF-1 concentrations in children with Crohn’s disease-induced growth failure: a pharmacokinetic study. BMJ. 2013; doi:10.1136/bmjopen-2013-002737.

  101. Hyams J, Walters TD, Crandall W, Crandall W, Kugathasan S, Griffiths A, Griffiths A, Blank M, et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extension. Curr Med Res Opin 2011 Mar;27(3):651-62

  102. Thayu M, Leonard MB, Hyams JS, Crandall WV, Kugathasan S, Otley AR, et al. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn’s disease: results of the REACH study. Clin Gastroenterol Hepatol. 2008;6(12):1378–84.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

MA is funded by the Higher Education Ministry of Libyan Government for a postgraduate studentship and this funding was used to support the writing of this manuscript. The IBD team at Yorkhill Hospital Glasgow is supported by the Catherine McEwan Foundation and Yorkhill IBD fund. RKR is supported by an NHS Research Scotland career fellowship award. SFA is supported by the Chief Scientist Office of Scotland and Ispen.

Conflicts of Interest

RKR has received consultation fees, research grants, or honorarium, from MSD, Abbott, Dr Falk, Ferring and Nestle. FA has received consultation fees and research grants from Novo Nordisk and Ipsen. MA has no conflicts of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S. Faisal Ahmed.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Altowati, M.A., Russell, R.K. & Ahmed, S.F. Endocrine Therapy for Growth Retardation in Paediatric Inflammatory Bowel Disease. Pediatr Drugs 16, 29–42 (2014). https://doi.org/10.1007/s40272-013-0046-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40272-013-0046-0

Keywords